Ricevi le ultime notizie sulle azioni MediWound con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MDWD

Ultime notizie per

MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

MediWound Ltd

News

Health Care

Press Releases

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Report First Quarter 2025 Financial Results

Biotech

General

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

Earnings

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

MediWound to Report Second Quarter 2025 Financial Results

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

MDWD

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

ALT5 Sigma

Alto Neuroscience

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Cybin

Journey Medical Corporation - Common Stock

Journey Medical

Evolus

High Tide

LB Pharmaceuticals

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Organigram Global

Omeros

Cassava Sciences

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

MediWound Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO